Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2016

View Archived Issues

Daiichi Sankyo reviews events of fourth quarter of fiscal 2015

Ono Pharmaceutical enters into option agreement with IDAC Theranostics for IT-1208

Theranexus presents promising results for TNH-102 in excessive daytime sleepiness

Patient-derived models could facilitate discovery of drugs for NSCLC harboring exon-20 insertions

Novel experimental mouse models of Brazilian Zika virus infection

Evestra describes first-in-class leukemia inhibitory factor inhibitor

Novel, dual IDO1/TDO inhibitor RG-70099 is active in vivo

PfSPZ Vaccine provides durable protection against malaria

Indivior announces dopamine receptor inhibitors

Genoscience Pharma patents antineoplastic compounds

Pfizer presents TRPA1 antagonists

Merck & Co. announces ROMK channel blockers

Karus Therapeutics introduces histone deacetylase inhibitors

Agios and Celgene form new metabolic immuno-oncology collaboration

Merck & Co. initiates phase I study of MK-4280 in patients with advanced solid tumors

Oramed's phase IIb trial of ORMD-0801 meets primary endpoints

ANAVEX 2-73 reduces epileptic spasms in infant rats

FDA approves Tecentriq and complementary diagnostic for metastatic urothelial carcinoma

Monaleesa-2 trial of ribociclib achieves meaningful improvement in PFS

Lynparza does not achieve primary OS endpoint in phase III GOLD trial

Phase I cohort results for mirvetuximab soravtansine in FRalpha-positive ovarian cancer

Novartis creates two new divisions, Novartis Pharmaceuticals and Novartis Oncology

GeoVax Labs plans new trial of HIV vaccine GOVX-B11

Gilead Sciences completes acquisition of Nimbus Apollo

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026